PT-141 for sexual health: what the FDA approval actually means

What did @paulbakhtiar actually say?

The creator made five distinct claims about PT-141 (bremelanotide): it is the top peptide for sexual health, it is FDA-approved for women, it increases sexual frequency, desire, and orgasm scores, it is safe for men, and it "bypasses the cardiovascular system" by acting on the MC4 receptor, making it safer than PDE5 inhibitors like sildenafil. That last claim is where things get complicated, and it deserves real scrutiny.

To be clear about framing: this is a short-form TikTok clip, not a clinical consultation. But 40,000 people watched it, and incomplete framing around a drug with known cardiovascular effects is not a small problem.

Does the science back this up?

Partially, yes. Bremelanotide (Vyleesi) received FDA approval in June 2019 specifically for premenopausal women with hypoactive sexual desire disorder (HSDD). The pivotal trials, specifically Clayton et al. (2016, Journal of Sexual Medicine), showed statistically significant improvements in desire and reductions in distress, though effect sizes were modest. The orgasm score improvement the creator references does appear in some study endpoints, though it was not the primary outcome.

The MC4 receptor mechanism is real. Unlike sildenafil, which works peripherally on vascular smooth muscle, bremelanotide acts centrally via melanocortin receptors in the hypothalamus. That distinction is scientifically legitimate. However, the phrase "bypasses the cardiovascular system" is where this claim breaks down badly. The FDA label for Vyleesi includes an explicit warning about transient increases in blood pressure following each dose, sometimes up to 6 mmHg systolic. That is a cardiovascular effect, full stop.

What did they get wrong (or right)?

They got the FDA approval status right. They got the mechanism right in broad strokes. They got the libido and desire data roughly right for women with HSDD.

What they got wrong matters more. Saying bremelanotide "bypasses the cardiovascular system" is inaccurate and potentially dangerous framing. The drug has a black-box-adjacent warning: it is contraindicated in patients with cardiovascular disease, and the label explicitly states blood pressure should not be monitored with a cuff during the 12-hour post-dose window because it can give false readings. The FDA approved it with a Risk Evaluation and Mitigation Strategy (REMS) program specifically because of these concerns.

The claim about "erection size" also lacks clinical support. The evidence for bremelanotide in men is limited and not FDA-approved for that indication. Simon et al. (2019, Journal of Sexual Medicine) showed some signal for erectile function in men, but "erection size" as a specific outcome is not established in the peer-reviewed literature. Saying it increases erection size is an overreach.

• Cardiovascular safety claim: inaccurate. The drug causes transient hypertension.
• FDA approval for women with HSDD: accurate.
• Central MC4 receptor mechanism: accurate.
• "Erection size" improvement in men: not supported by current evidence.
• Safer than PDE5 inhibitors categorically: misleading without context.

What should you actually know?

Bremelanotide is a real, FDA-approved drug with a specific indication: premenopausal women with acquired, generalized HSDD. That is a narrower population than "women" broadly. It is not approved for men in any jurisdiction as of this writing, and off-label use in men exists but has limited controlled trial data. Anyone considering it should know: nausea is the most commonly reported side effect, occurring in roughly 40 percent of patients in trials. The blood pressure effect is real and clinically meaningful for anyone with hypertension or cardiovascular risk factors.

Comparing it to "blue pills" as categorically safer ignores that PDE5 inhibitors have decades of safety data across millions of patients. Bremelanotide was approved in 2019 and has a much shorter post-market safety record. Neither drug is universally safer. They work differently, and the comparison requires a real clinical conversation, not a TikTok.

Compounded versions of PT-141 circulating in the peptide market are not the same as FDA-approved Vyleesi. Purity, dosing accuracy, and sterility are not guaranteed outside regulated pharmacy channels.